CBM Streamlines Cell and Gene Therapy Manufacturing Capabilities with Autolomous Digital Platform

Published on :

In its quest to be one of the top Contract Development and Manufacturing Organizations in the world, the Center for Breakthrough Medicines (CBM) will implement a robust digital solutions system that will support end-to-end cell and gene therapy manufacturing processes.

Meet Your 2022 BioBuzz Award Winners

Published on :

Today, we are excited to announce the winners of our 3rd Annual BioBuzz Awards. The BioBuzz Awards are a celebration of the exciting and groundbreaking work being done by the BioHealth Capital Region (BHCR) and Greater Philadelphia life science communities and the individuals that make innovation happen.

End-to-End Manufacturing at a Single Site and High-throughput Vector Suite Design Will Bolster Batch Production Up to Five Times

Published on :

King of Prussia, PA — December 08, 2022 —The Center for Breakthrough Medicines (CBM), a contract development, manufacturing, and testing organization (CDMO) has launched Genesis Vector Manufacturing SolutionsTM to help innovator companies reimagine vector manufacturing by simplifying the value chain and accelerate their path to clinic and commercial launch.
CBM’s Genesis Vector Manufacturing SolutionsTM is an end-to-end offering that includes plasmid manufacturing, first-time right process development and high-throughput GMP vector manufacturing suites to accelerate development and manufacturing timelines. Integrated testing & analytics, supply chain, and regulatory services co-located with manufacturing at a single site drastically simplifies the vector value chain. CBM’s new, purpose-built facility is engineered and outfitted to support a wide variety of vectors, including viral-based products (such as those used for gene-modified cell therapies in CBM’s previously announced expansion) as well as other novel biologically derived delivery vectors compliant with the most robust segregation controls.
“This past year has been a catalyst moment for gene therapies with approvals and authorizations doubling the number of treatments available, accelerating the need for high throughput manufacturing of diverse vectors used to deliver lifesaving therapies,” said Audrey Greenberg, CBM’s Co-founder and Chief Business Officer. “We are thrilled to complete phase one of…

Announcing Your 3rd Annual BioBuzz Awards Finalists

Published on :

We’re excited to announce this year’s finalists for the third annual 2022 BioBuzz Awards. These awards celebrate the people and companies across our regional community and their efforts and accomplishments to impact human health and build a stronger biotech community.

C-Suite Women in Greater Philly’s Life Science Scene You Should Know

Published on :

As long overdue change takes shape and the number of women in the biotech industry continues to grow, it is important to recognize those that have created the path for the next generation of diverse leaders. BioBuzz wishes to acknowledge the incredible contributions and efforts of women who have made their mark on the industry. 

Center for Breakthrough Medicines (CBM) and jCyte Announce Strategic Partnership to Manufacture jCyte’s Innovative Cell Therapy for Treatment of Retinal Degenerative Diseases

Published on :

The Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization (CDMO) dedicated to addressing the unique requirements associated with commercializing cell and gene therapies, and jCyte, a clinical-stage biotech company focused on preserving and restoring vision in patients with retinitis pigmentosa (RP) and other retinal degenerative diseases, today announced a multi-year manufacturing agreement wherein CBM will be the primary manufacturer of jCyte’s U.S. Food & Drug Administration’s Regenerative Medicine Advanced Therapy (RMAT) designated cell therapy, jCell. Under the terms of the agreement, CBM will provide Phase 3 clinical trial supplies and commercial drug product following Biologics License Application (BLA) approval of jCyte’s proprietary jCell platform technology. CBM will also provide all BLA-enabling Chemistry, Manufacturing and Controls (CMC) work to support the program through regulatory approval and commercialization.

5 Questions With Shailah Yazdani, Director of Operations at the Center for Breakthrough Medicines

Published on :

Passionate about driving the next generation of provider and patient care offerings, Shailah Yazdani has dedicated more than 15 years to creating and modernizing organizational systems and delivering best-in-class healthcare solutions. Focusing on the company vision and mission, Shailah works with industry leaders to solve multi-layered challenges, designing innovative systems to create value and ignite enterprise growth.

Center for Breakthrough Medicines, QIAGEN Team Up to Raise Funds for Emily Whitehead Foundation

Published on :

Since Kymriah’s first approval in 2017, six CAR T-cell therapies have been approved by the FDA, all for different forms of blood cancer, such as lymphomas, leukemia, and multiple myeloma. As Gottlieb predicted, cell therapies have provided significant hope for cancer patients, both young and old, with many of them enjoying results they had not experienced with other therapies.

Life Science Leaders Share Optimism, Discuss Opportunities at Philadelphia Life Science Summit

Published on :

The buzz around the summit was one of enthusiasm as Philly strives to join the top tier of life sciences hub in the country. The life sciences scene in Philly is growing and may soon be approaching an inflection point preceding rapid growth, reminiscent of 1990s Boston. The Summit examined the dynamic Philly landscape as a whole, both celebrating recent successes and talk about the hurdles that must be overcome for the ecosystem to truly thrive.

Center for Breakthrough Medicines Plans for an Even Larger Dive into Cell Therapy Manufacturing

Published on :

As the pipeline for cell ther­a­pies grows, man­u­fac­tur­ers and CD­MOs are look­ing to get in on the ac­tion.
The Cen­ter for Break­through Med­i­cines, a Penn­syl­va­nia-based CD­MO, is part­ner­ing with Dis­cov­ery Labs to ac­cel­er­ate plans to build the ca­pac­i­ty to man­u­fac­ture more than 10,000 pa­tient ther­a­pies at their head­quar­ters in King of Prus­sia, PA, a sub­urb of Philadel­phia.
The plan­ning has be­gun on the man­u­fac­tur­ing suites and sup­port­ing in­fra­struc­ture, and when com­plet­ed the fa­cil­i­ty, ac­cord­ing to CBM’s con­ser­v­a­tive cal­cu­la­tions, the site will be able to pro­duce around 10,000 batch­es of prod­uct per year in the space.